Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
$492m pathology hub coming to Westmead Health Precinct
The NSW Health Pathology Statewide Hub will be delivered to Westmead Health Precinct, as part of...
WA Govt appoints Sharath Sriram as Chief Scientist
A distinguished science and research leader with 20 years of experience in science and...
$50m donation for new endometriosis research institute
Three generations of the philanthropic Ainsworth family have committed a total of $50 million...